Patents by Inventor Mitsuhiro Makino

Mitsuhiro Makino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10495658
    Abstract: An automatic analyzer with high processing capacity is capable of immediately measuring an emergency specimen rack. The automatic analyzer includes a conveying line for conveying a specimen rack, and an analysis unit which has a dispensing line in which a plurality of specimen racks are arranged for waiting until sample dispensing, and a sampling area for dispensing the sample to the analysis unit. A rack save area is provided in the dispensing line and at a position adjacent to the upstream side of the sampling area. When a specimen rack exists in the sampling area at the time of measuring an emergency specimen rack, a controller moves the specimen rack to the save area and positions the emergency specimen rack to be moved from a downstream side of the sampling area to the sampling area.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: December 3, 2019
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Akihisa Makino, Mitsuhiro Hishinuma, Toshiyuki Shimamori, Masato Ishizawa
  • Publication number: 20190338002
    Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.
    Type: Application
    Filed: July 8, 2019
    Publication date: November 7, 2019
    Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
  • Patent number: 10400016
    Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 3, 2019
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
  • Publication number: 20170166615
    Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.
    Type: Application
    Filed: December 7, 2016
    Publication date: June 15, 2017
    Applicant: Daiichi Sankyo Co., Ltd.
    Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
  • Publication number: 20120101137
    Abstract: The object of the present invention is to provide a compound having a glucokinase-activating effect. A pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein X means a nitrogen atom or CR6, wherein R6 means a hydrogen atom or a halogen atom; R1 means a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkylthio group; R2 means a hydrogen atom or a fluorine atom; R3 means a hydrogen atom or a C1-C6 alkyl group; and one of R4 and R5 means a hydrogen atom or a C1-C6 alkyl group, and the other means a C1-C6 alkylenecarboxylic acid, a C1-C6 alkylsulfonyl group, a C1-C6 alkylcarbonyl group, or CONH2.
    Type: Application
    Filed: June 26, 2010
    Publication date: April 26, 2012
    Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.
    Inventors: Tokuyuki Yamashita, Kaori Chikamatsu, Naoki Takahashi, Hisakazu Iwai, Masakazu Kogami, Masao Sakairi, Nobuhide Watanabe, Hiroki Fujieda, Daisuke Kataoka, Mitsuhiro Makino, Noriyasu Kato, Toshiyuki Miyazawa, Kazushige Nagai, Nobuyoshi Kasugai, Hiroyo Kataoka, Naoki Hiramatsu, Nobuaki Tsuruta, Yurie Yamada, Mika Miyoshi, Sei Murakami, Izumi Goto, Tohru Izuchi, Kimie Suzuki, Satoko Harada, Martin Lang, Markus Hans-Juergen Seifert, Kristina Kaarina Wolf
  • Patent number: 7345180
    Abstract: A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or —COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1, R2, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4represents a hydrogen or a cyano group, D represents —CONR6-, —CO— or —NR6CO—, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents —(CH2)m— whereupon m is 1 to 3, —CH2OCH2—, or —SCH2—, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: March 18, 2008
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Takuji Kakigami, Mitsuru Oka, Noriyasu Katoh, Masahiro Yoshida, Masahiro Shirai, Toru Murase, Masao Sakairi, Takayo Murase, Mitsuaki Takeuchi, Yuji Hayashi, Motohiro Takeda, Mitsuhiro Makino
  • Patent number: 7291594
    Abstract: A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH2, Lys, Lys-NH2 or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are highly absorbable via a mucous membrane. The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively. The absorption efficiency of the GLP-1 derivatives via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: November 6, 2007
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Yuji Hayashi, Mitsuhiro Makino, Toshiyuki Kouzaki, Motohiro Takeda, Takahito Jomori
  • Publication number: 20060229286
    Abstract: A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or —COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1, R2, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4 represents a hydrogen or a cyano group, D represents —CONR6—, —CO— or —NR6CO—, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents —(CH2)m— whereupon m is 1 to 3, —CH2OCH2—, or —SCH2—, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 12, 2006
    Inventors: Takuji Kakigami, Mitsuru Oka, Noriyasu Katoh, Masahiro Yoshida, Masahiro Shirai, Toru Murase, Masao Sakairi, Takayo Murase, Mitsuaki Takeuchi, Yuji Hayashi, Motohiro Takeda, Mitsuhiro Makino
  • Publication number: 20060194720
    Abstract: The invention relates to a GLP-1 derivative including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH2, Lys, Lys-NH2 or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are derivatives highly absorbable via a mucous membrane. In the invention, the GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively. The efficiency of absorption of the GLP-1 derivatives of the invention via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.
    Type: Application
    Filed: October 10, 2003
    Publication date: August 31, 2006
    Inventors: Yuji Hayashi, Mitsuhiro Makino, Toshiyuki Kouzaki, Motohiro Takeda, Takahito Jomori